The evolution of aldosterone antagonists.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Molecular and Cellular Endocrinology

• Publication date

  2004-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.MCE.2003.10.005PMID 15134797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eplerenone: a selective aldosterone receptor antagonist (SARA).

  2006cited by this paper
• Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism

  2004cited by this paper
• The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction

  2004cited by this paper
• Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension

  2003cited by this paper
• Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.

  2003cited by this paper
• Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure

  2002cited by this paper
• P-499: Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients

  2002cited by this paper
• Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.

  2002cited by this paper
• Aldosterone induces a vascular inflammatory phenotype in the rat heart.

  2002cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients

  2002cited by this paper
• Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.

  2001cited by this paper
• Effect of a selective aldosterone receptor antagonist in myocardial infarction.

  2001cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Remodeling of the rat right and left ventricles in experimental hypertension.

  1990cited by this paper
• Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

  1987cited by this paper
• THE METABOLISM AND BIOPHARMACEUTICS OF SPIRONOLACTONE IN MAN

  1987cited by this paper
• Mechanism of action of a new antialdosterone compound, prorenone.

  1979cited by this paper
• SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.

  1979cited by this paper
• Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.

  1978cited by this paper
• Gynecomastia induced in normal males by spironolactone

  1978cited by this paper
• SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate.

  1978cited by this paper
• Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man

  1977cited by this paper
• Mechanisms regulating renin release.

  1976cited by this paper
• Antiandrogenic effect of spirolactones: mechanism of action.

  1975cited by this paper
• Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.

  1974cited by this paper
• Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.

  1973cited by this paper
• Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder.

  1970cited by this paper
• Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder.

  1970cited by this paper
• Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors.

  1968cited by this paper
• STEROIDAL ALDOSTERONE BLOCKERS. VII.

  1963cited by this paper
• Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion.

  1961cited by this paper
• Protection by a Steroid-Spirolactone Against Certain Types of Cardiac Necroses.∗

  1960cited by this paper
• Prevention by adrenal-regeneration hypertension by an aldosterone-blocker.

  1959cited by this paper
• Steroidal Aldosterone Blockers. III1,2

  1959cited by this paper
• Prevention by adrenal-regeneration hypertension by an aldosterone-blocker.

  1959cited by this paper
• Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt.

  1957cited by this paper
• The metabolic effects of progesterone in man.

  1955cited by this paper
• Isolierung eines neuen kristallisierten Hormons aus Nebennieren mit besonders hoher Wirksamkeit auf den Mineralstoffwechsel

  1953cited by this paper
• [Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism].

  1953cited by this paper

• Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution

  2026cites this paper
• Approved Steroidal Drugs (2000-2025): A Medicinal Chemistry Perspective.

  2026cites this paper
• Intriguing the significance of hydrophobic groove by the inhibitory mechanism of mineralocorticoid receptor bound with spironolactone through mutations using long-range molecular dynamics simulations in conjunction with statistical analysis

  2026cites this paper
• Visible-light induced sustainable photochemical approach for the synthesis of spirocyclic compounds.

  2026cites this paper
• Spironolactone inhibits the NLRP1 inflammasome and alleviates defective erythropoiesis in Diamond‐Blackfan anemia

  2025cites this paper
• Injectable estradiol monotherapy effectively suppresses testosterone in gender-affirming hormone therapy.

  2025cites this paper
• The role of combined Metformin and pharmaceutical molecules with anti-androgenic properties in the therapy of PCOS in adult women

  2025cites this paper
• Spiro-Heterocycles: Recent Advances in Biological Applications and Synthetic Strategies

  2025cites this paper
• Efficacy and safety of finerenone in the treatment of primary aldosteronism: A prospective clinical study.

  2025cites this paper
• Photoinduced Spirocyclization for the Synthesis of Spirocyclic Compounds.

  2025cites this paper
• A Divergent Synthesis of Spiroindenes via Ligand‐Controlled [3+2]/[4+2] Cycloadditions of Zwitterionic π‐Propargyl Palladium Species with Benzofulvenes

  2025cites this paper
• Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease

  2025cites this paper
• Aldosterone-mediated hypertension and non-steroidal mineralocorticoid receptor antagonists.

  2025cites this paper
• Novel drug design and repurposing: An opportunity to improve translational research in cardiovascular diseases?

  2024cites this paper
• Clinical implications of mineralocorticoid receptor overactivation

  2024cites this paper
• Is It Primetime for Finerenone in Heart Failure?

  2024cites this paper
• Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

  2024cites this paper
• Catalyst-Free Three-Component Synthesis of Novel Tetrahydrospiro[indole-3,3′-pyrazole] Derivatives

  2024cites this paper
• Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

  2023cites this paper
• Mineralocorticoid receptor antagonists in cardiovascular translational biology

  2023cites this paper
• Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists

  2023cites this paper
• Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis

  2023cites this paper
• Current Landscape of Therapeutics for the Management of Hypertension - A Review.

  2023cites this paper
• Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease

  2023cites this paper
• Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis

  2023cites this paper
• Research Progress in Finerenone in Cardiovascular Diseases

  2023cites this paper
• Highly congested spiro-compounds via photoredox-mediated dearomative annulation cascade

  2022cites this paper
• The challenging role of antiandrogens in the management of polycystic ovary syndrome

  2022cites this paper
• A novel spirocyclic scaffold accessed via tandem Claisen rearrangement/intramolecular oxa-Michael addition

  2022cites this paper
• Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure

  2022cites this paper
• Multi-Spectroscopic, thermodynamic and molecular docking studies to investigate the interaction of eplerenone with human serum albumin.

  2022cites this paper
• Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review

  2022cites this paper
• Mineralocorticoid Receptor Antagonist Treatment of Established Pulmonary Arterial Hypertension Improves Interventricular Dependence in SU5416-Hypoxia Rat Model.

  2022cites this paper
• Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide

  2022cites this paper
• Cure and Long-Term Remission Strategies.

  2022cites this paper
• The mineralocorticoid receptor—an emerging player in metabolic syndrome?

  2021cites this paper
• Renin-Angiotensin-Aldosterone System

  2021cites this paper
• A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids

  2021cites this paper
• Penggunaan Mineralocorticoid Receptor Antagonist pada Heart Failure Reduced Ejection Fraction

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonism for cardiovascular and renal disorders - new perspectives for combination therapy.

  2021cites this paper
• Systemic pharmacological treatments for acne: an overview of systematic reviews

  2021cites this paper
• Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

  2021cites this paper
• Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents.

  2021cites this paper
• Diuretic Agents

  2021cites this paper
• Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing.

  2021cites this paper
• The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

  2021cites this paper
• Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology

  2021cites this paper
• Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

  2021cites this paper
• Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver

  2020cites this paper
• The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency

  2020cites this paper
• New drug targets for hypertension: A literature review.

  2020cites this paper
• Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.

  2020cites this paper
• Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

  2020cites this paper
• Spirocyclic Scaffolds in Medicinal Chemistry.

  2020cites this paper
• Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?

  2019cites this paper
• Acne Vulgaris: Pimples Do Not Have Simple Solution

  2019cites this paper
• Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1‐7)/MAS receptor axes in human mesangial cells

  2019cites this paper
• ACNE PROTECTION: MEASURES AND MISERIES

  2019cites this paper
• of Clinical Pharmacy

  2019cites this paper
• Corticosterone in the ventral hippocampus differentially alters accumbal dopamine output in drug-naïve and amphetamine-withdrawn rats.

  2019cites this paper
• Diuretics

  2019cites this paper
• Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension.

  2019cites this paper
• Adverse Effects of Mineralocorticoid Receptor Antagonist Administration.

  2019cites this paper
• The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

  2019cites this paper
• Ocular biodistribution of spironolactone after single intravitreal injection of a biodegradable sustained release polymer in rats.

  2019cites this paper
• Acne Vulgaris

  2019cites this paper
• Acne Protection: Measures & Miseries

  2018cites this paper
• Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

  2018cites this paper
• Primary hyperaldosteronism in the composition of arterial hypertension: diagnosis and treatment

  2018cites this paper
• Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo‐controlled cross‐over study

  2018cites this paper
• Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy

  2018influential citation
• 24 – Renin Angiotensin Aldosterone System Blockers

  2018cites this paper
• Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

  2017cites this paper
• Impact of Adrenal Steroids on Regulation of Adipose Tissue.

  2017influential citation
• Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.

  2017cites this paper
• Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review

  2017cites this paper
• Renin-angiotensin system blockade: Finerenone.

  2017cites this paper
• Metabolomics for informing adverse outcome pathways: Androgen receptor activation and the pharmaceutical spironolactone.

  2017influential citation
• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

  2017influential citation
• Aldosterone and the mineralocorticoid receptor in insulin resistance and diabetes

  2017cites this paper
• Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first‐in‐man and relative bioavailability studies

  2016cites this paper
• The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.

  2016cites this paper
• Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism

  2016cites this paper
• Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.

  2016cites this paper
• Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.

  2016cites this paper
• Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment

  2016influential citation
• Comparison of Spironolactone versus Amlodipine in Hypertensive Cardiorenal Pathology

  2016cites this paper
• New approaches in the treatment of hypertension.

  2015cites this paper
• [Role of morphofunctional adrenal changes in pathogenesis of water-electrolyte disorders in patients with acute intestinal obstruction].

  2015cites this paper
• Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

  2015cites this paper
• Mineralcorticoid Receptor Antagonists

  2015cites this paper
• Adrenal Steroid Hormones

  2015cites this paper
• Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

  2015cites this paper
• Pharmaceuticals and personal care products: A critical review of the impacts on fish reproduction

  2015cites this paper
• Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.

  2015cites this paper
• Human steroidogenic cytochromes P450 : biotransformation of drugs and biotechnological application

  2015cites this paper
• Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods

  2015cites this paper
• Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.

  2015influential citation
• Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis

  2015cites this paper
• Pharmacological treatment of aldosterone excess.

  2015cites this paper